Alvotech Issues Annual Equality Report Covering 2022
15 mai 2023 05h00 HE
|
Alvotech
Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is...
Alvotech birtir skýrslu um þróun jafnréttismála á árinu 2022
15 mai 2023 05h00 HE
|
Alvotech
Hlutfall karla og kvenna í starfsliði Alvotech er nú jafnt og óútskýrður kynbundinn launamunur dróst saman úr 5,2% í desember 2020 í 1,6% í desember 2022Jafnréttisstefna Alvotech fylgir íslenskri...
Alvotech Issues Annual Equality Report Covering 2022
15 mai 2023 05h00 HE
|
Alvotech
Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is...
Alvotech semur við Polifarma um markaðssetningu fyrirhugaðrar líftæknilyfjahliðstæðu við Eylea (aflibercept)
10 mai 2023 05h00 HE
|
Alvotech
Polifarma öðlast rétt til að markaðssetja AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea® (aflibercept) í Tyrklandi Alvotech (NASDAQ: ALVO) tilkynnti í dag um undirritun samnings við Polifarma...
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
10 mai 2023 05h00 HE
|
Alvotech
Polifarma will commercialize AVT06, a proposed biosimilar to Eylea® (aflibercept), in Turkey Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of...
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
10 mai 2023 05h00 HE
|
Alvotech
Polifarma will commercialize AVT06, a proposed biosimilar to Eylea® (aflibercept), in Turkey REYKJAVIK, Iceland, May 10, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...
Aðalfundur Alvotech S.A. boðaður 6. júní 2023
05 mai 2023 09h00 HE
|
Alvotech
Aðalfundur Alvotech S.A. verður haldinn þriðjudaginn 6. júní 2023, kl. 09.00 CEST á skrifstofu Arendt & Medernach S.A að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Drög af dagskrá fundarins...
Alvotech S.A. Annual General Meeting to be held June 6, 2023
05 mai 2023 09h00 HE
|
Alvotech
The Annual General Meeting of Alvotech S.A. will be held on Tuesday 6 June 2023, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg,...
Alvotech birtir uppgjör fyrsta ársfjórðungs 2023 þann 18. maí nk. og heldur kynningarfund 19. maí nk. kl. 12 að íslenskum tíma
03 mai 2023 09h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) mun birta uppgjör fyrsta ársfjórðungs 2023 eftir lokun markaða í Bandaríkjunum, fimmtudaginn 18. maí 2023. Þá mun Alvotech halda kynningarfund fyrir fjárfesta í beinu streymi...
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
03 mai 2023 09h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...